Jennifer Donglan Wu

  • 3360 Citations
1990 …2023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

I joined Northwestern University in August 2017 as a tenured Professor in Urology. I previously served as a Professor of Microbiology and Immunology at the Medical University of South Carolina and the University of Washington. I obtained a PhD from the University of British Columbia in Canada followed by post-doctoral training in Fred Hutchinson Cancer Research Center (FHCRC) and a faculty position at the University of Washington. My research focuses on understanding how cancer cells edit the immune system with the ultimate goal to develop effective immune therapy to control cancers.

Research in my laboratory include these specific aspects: 1) mechanisms of cancer immune evasion; 2) development of novel cancer immunotherapy; 3) Immune therapy-related mucosal toxicity; 4) mechanisms of cancer therapeutic resistance; 4) cancer biomarker discovery. Prostate Cancer is one of my lab's main focus areas. I am also researching the NKG2D axis in tumors which can be applied to a broad spectrum of cancer types and autoimmunity.

Training Experience

2002Postdoctoral Fellowship, Fred Hutchinson Cancer Research Center

Education/Academic qualification

PhD, University of British Columbia

… → 2000

MSc, Peking University

… → 1991

Research interests

  • Cancer Biology
  • Immune Regulation
  • Inflammation
  • Inflammatory Bowel Disease
  • Interdisciplinary Research
  • Prostate Cancer

Fingerprint Dive into the research topics where Jennifer Donglan Wu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

  • Research Output

    • 3360 Citations
    • 45 Article
    • 6 Review article
    • 1 Comment/debate
    • 1 Editorial

    How else can we approach prostate cancer biomarker discovery?

    Drake, R. R., Angel, P. M., Wu, J., Pachynski, R. K. & Ippolito, J. E., Feb 1 2020, In : Expert Review of Molecular Diagnostics. 20, 2, p. 123-125 3 p.

    Research output: Contribution to journalEditorial

    Open Access
    1 Scopus citations
    Open Access
  • 1 Scopus citations

    CD73: An emerging checkpoint for cancer immunotherapy

    Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y. & Zhang, B., Jan 1 2019, In : Immunotherapy. 11, 11, p. 983-997 15 p.

    Research output: Contribution to journalReview article

  • 4 Scopus citations

    Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

    Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C., Lukas, R. V., Binder, D. C. & Wainwright, D. A., Mar 4 2019, In : OncoImmunology. 8, 3, 1548242.

    Research output: Contribution to journalComment/debate

  • Past, Current, and Future of Immunotherapies for Prostate Cancer

    Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. & Wu, J. D., Sep 11 2019, In : Frontiers in Oncology. 9, 884.

    Research output: Contribution to journalReview article

    Open Access
  • 2 Scopus citations